I Know I Know, But I Just Had to Check Back on GANX

#1 Ticker That’s Still in Focus!

(Nasdaq: GANX)

Hey everyone,

If you haven’t checked out Friday’s post yet, go ahead and take a look so you don’t miss any of the major news that went on last week.

And as it turns out, there was also something going on with Gain Therapeutics last week that’s worth circling back to.

The ticker pulled back a bit on Friday, so it felt like a good time to check back in and see where things stand.

I’m not sure if you already saw.

But they had news come out last week…

Here’s What Happened

Last Thursday, Gain Therapeutics announced it will be presenting interim Phase 1b clinical data for its Parkinson’s drug candidate GT-02287 at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders.

The company also said it submitted additional preclinical data requested by the FDA related to its Investigational New Drug (IND) application and expects feedback from the agency in the coming weeks.

And If things continue moving forward as expected, the company still plans to begin a Phase 2 clinical trial in Q3 2026.

The presentation is set to kick off in the next couple days on March 18th.

That gives me some time to see how it trades today and tomorrow. Given how the ticker reacted back in February, keeping an eye out wouldn’t hurt.

So with that coming up, there are a few things I’ll be paying attention to from here.

The Potential Catalysts

The first one is the data presentation at the AD/PD conference. With new clinical data being shared publicly this week, I’ll be watching how the ticker behaves leading up to it and after.

There are also a few other developments that could matter depending on how things unfold.

But of course, what really matters is how the price actually reacted.

Here’s What I’m Seeing on the Chart

GANX closed Friday at $2.43, which puts it right in the middle of the range we’ve been watching over the past couple of weeks.

The price dropped a little over 11% on Friday, bringing it down about 20% for the week, though it’s still up roughly 34% over the past month.

Volume also stayed fairly active during the pullback. The ticker traded over a million shares earlier in the week, followed by several sessions in the 600,000–700,000 range, before picking back up again with around 1.2 million shares on Friday.

So now, the focus shifts back to the levels we’ve been talking about.

The first level underneath is still $2.36, which has been the most recent support on my chart. Price pulled back right into that area during Friday’s move, so it remains the level I’m watching first. As long as $2.36 holds, this recent structure remains intact.

On the upside, there are a few levels that still need to be reclaimed.

The first ones I’m watching are $2.61 and $2.70. Above that sits $2.85, which is just above the $2.78 area we talked about during the previous move.

But I also noticed something when I zoomed out a bit further.

GANX has been trading inside a tightening range for a while now, going back a little further than 2024.

Long-term support sits around $2, while resistance has been coming down from above $4. With those levels gradually pressing toward each other, which could eventually lead to a breakout.

It will be interesting to see which side gives first as we’re only a few months into 2026.

Before We Wrap Up

As always, make sure to do your own research and review company filings, press releases, and official resources if you want more context around the company and its development programs.

I’ll be back on Friday with the weekly market recap, so keep an eye out for that in your inbox.

And don’t forget, March Madness is right around the corner, so make sure those brackets are ready.

I have a feeling mine will be perfect this year.

Stay sharp,

Brandon Parks.

Disclaimer: The information in this communication is for informational and educational purposes only and does not constitute financial, legal, or tax advice. I am not a licensed financial advisor. The views, ideas, and any security mentions expressed are my personal opinions, are subject to change, and are not a recommendation to buy or sell. No warranty is made regarding the accuracy or completeness of this information. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal. You should consult a qualified financial professional to determine the suitability of any investment for your specific situation and always conduct your own due diligence. Neither I nor Earnings Alpha shall be held liable for any losses or damages arising from any action taken based on this content. We do not currently hold positions in the securities mentioned above.